1.Minute on the 6th session of national conference of deficiency syndrome and gerontology.
Chinese Journal of Integrated Traditional and Western Medicine 2002;22(6):478-479
Aging
;
drug effects
;
Cerebral Infarction
;
drug therapy
;
China
;
Dementia
;
drug therapy
;
Humans
;
Yang Deficiency
;
drug therapy
2.Fangji Dihuang Decoction formula syndrome and Fengyin Decoction formula syndrome:application in stroke and mental disorders.
China Journal of Chinese Materia Medica 2019;44(3):602-607
Fangji Dihuang Decoction and Fengyin Decoction, which were firstly recorded in Synopsis of the Golden Chamber, could be used to treat stroke. However, both of these two decoctions are used infrequently. There is a clear pathogenesis of modern pathophysiology behind Fangji Dihuang Decoction syndrome and Fengyin Decoction syndrome, which can be interpreted by modern language of science. Fangji Dihuang Decoction can nourish Yin, tonify kidney, extinguish the wind, and dredge collaterals. It could be used to treat mania caused by cerebral infarction, senile dementia, Alzheimer's disease and other cerebrovascular diseases, and opened up the precedent of nourishing Yin and expelling wind to treat stroke in later generations. Fengyin Decoction can clear heat, extinguish the wind, and calm the mind. It can be used to treat cerebral infarction, limb paralysis and epileptic seizures with heat syndrome. It may be equivalent to "oriental olanzapine", and opened up the precedent of smoothing liver and suppressing Yang to treat stroke in later generations. They can be used in the combination, with a high application value in treating stroke and mental diseases.
Cerebral Infarction
;
drug therapy
;
Drugs, Chinese Herbal
;
therapeutic use
;
Humans
;
Medicine, Chinese Traditional
;
Mental Disorders
;
drug therapy
;
Stroke
;
drug therapy
3.CiteSpace knowledge map analysis of Angong Niuhuang Pills in recent twenty years.
Xue BAI ; Fei-Fei GUO ; Lin TONG ; Hong-Jun YANG
China Journal of Chinese Materia Medica 2023;48(5):1381-1392
Angong Niuhuang Pills, a classical formula in traditional Chinese medicine, are lauded as one of the "three treasures of febrile diseases" and have been widely used in the treatment of diverse disorders with definite efficacy. However, there is still a lack of bibliometric analysis of research progress and development trend regarding Angong Niuhuang Pills. Research articles on Angong Niuhuang Pills in China and abroad(2000-2022) were retrieved from CNKI and Web of Science. CiteSpace 6.1 was used to visualize the key contents of the research articles. In addition, the research status of Angong Niuhuang Pills was analyzed by information extraction to allow insight into the research trends and hotspots about Angong Niuhuang Pills. A total of 460 Chinese articles and 41 English articles were included. Beijing University of Chinese Medicine and Sun Yat-Sen University were the research institutions that have published the largest amount of research articles in Chinese and English. The keyword analysis showed that the Chinese articles focused on cerebral hemorrhage, stroke, neurological function, coma, cerebral infarction, craniocerebral injury, and clinical application, while the English articles focused on the mechanisms of cerebral ischemia, stroke, heavy metal, blood-brain barrier, and oxidative stress. Stroke, blood-brain barrier, and oxidative stress were presumably the research hotspots in the future. At present, the research on Angong Niuhuang Pills is still in the developing stage. It is necessary to highlight the in-depth research on the active components and mechanism of action and carry out large-scale randomized controlled clinical trials to provide references for the further development and application of Angong Niuhuang Pills.
Humans
;
Drugs, Chinese Herbal/therapeutic use*
;
Stroke/drug therapy*
;
Medicine, Chinese Traditional
;
Brain Ischemia/drug therapy*
;
Cerebral Infarction/drug therapy*
4.The application of qi benefiting and blood activating method in thrombolytic therapy of acute cerebral infarction.
Chinese Journal of Integrated Traditional and Western Medicine 2012;32(8):1126-1129
The thrombolytic therapy has been widely used in treating acute cerebral infarction (ACI), but various severe complications restrict its clinical application. However, Chinese medicine shows its advantages in the treatment of ACI after thrombolytic therapy. Qi benefiting and blood activating method is an important principle and mean for supporting the vital qi and removing the surplus evil. By using this method, its short-term and long-term efficacy could be improved after thrombolytic therapy.
Cerebral Infarction
;
drug therapy
;
Drugs, Chinese Herbal
;
therapeutic use
;
Humans
;
Medicine, Chinese Traditional
;
methods
;
Thrombolytic Therapy
6.Reasonable and safe application of Shuxuetong injection and intravenous medication's combined application in acute cerebral infarction's therapy.
Ming-Quan LI ; Yan-Ming XIE ; Jian-Jun ZHAO
China Journal of Chinese Materia Medica 2012;37(18):2742-2743
Shuxuetong injection is a kind of compound injection which is made from traditional Chinese medicine Hirudo and Pheretime, which has a clear anticoagulant, fibrinolytic promoting, blood rheology improving, blood lipids regulating and cell protecting effect, and the injection has been widely used in clinical. Especially, the injection has often been combined with other Chinese and modern medicine in the treatment of cerebral infarction disease. However, there are still many non-standard and irrational aspects in clinical practice so as to make a more reasonable and safer use of Shuxuetong injection. In order to avoid the occurrence of adverse reactions to provide a reference for regulating the use of the injection,the paper systematically expounds the Shuxuetong injection's main clinical problems and the reasonable combination.
Administration, Intravenous
;
Animals
;
Annelida
;
Cerebral Infarction
;
drug therapy
;
Drugs, Chinese Herbal
;
administration & dosage
;
adverse effects
;
Humans
7.Overview of systematic reviews of Panax notoginseng saponins in treatment of acute cerebral infarction.
Liu-Ding WANG ; Zhen-Min XU ; Xiao LIANG ; Wen-Ran QIU ; Shao-Jiao LIU ; Ling-Ling DAI ; Ye-Fei WANG ; Chun-Yan GUO ; Xiang-Hua QI ; Jian WANG ; Yan-Bing DING ; Yun-Ling ZHANG ; Xing LIAO
China Journal of Chinese Materia Medica 2021;46(12):2963-2971
To overview the systematic reviews of Panax notoginseng saponins in the treatment of acute cerebral infarction. CNKI, CBM, Wanfang, VIP, PubMed, Cochrane Library and EMbase databases were retrieved to collect the systematic reviews of the efficacy of P. notoginseng saponins in the treatment of acute cerebral infarction. The retrieval time was from the time of database establishment to January 2021. After two researchers independently screened out the literature and extracted the data, AMSTAR-2 scale was used to evaluate the methodological quality of the included systematic reviews, GRADE system was used to grade the quality of evidences of the outcome indicators, and the efficacy evaluation was summarized. A total of 5 systematic reviews were included. AMSTAR-2 evaluation results showed that 3 items were relatively complete, while 4 items had a poor overall quality. P. notoginseng saponins combined with conventional Western medicine therapy was superior to single conventional therapy in the recovery of neurological function, enhancement of the total effective rate in clinic, and improvement of activities of daily living. GRADE evaluation results showed that the quality of evidence was from low quality to very low quality. In conclusion, in the treatment of acute cerebral infarction, P. notoginseng saponins can improve the clinical efficacy, with a good safety but a not high methodological quality and a low evidence quality. It is suggested that high-quality clinical studies shall be further carried out to provide evidence-based basis for the application of P. notoginseng saponins in the treatment of acute cerebral infarction.
Activities of Daily Living
;
Cerebral Infarction/drug therapy*
;
Humans
;
Panax notoginseng
;
Saponins
;
Systematic Reviews as Topic
8.Systematic review and Meta-analysis of clinical efficacy and safety of Ginkgo Leaf Tablets in treatment of acute cerebral infarction.
Tian-Tian MENG ; Zi-Yu TIAN ; Xiao-Long XIE ; Ting-Ting LI ; Wei-di LIU ; Ying GAO
China Journal of Chinese Materia Medica 2021;46(6):1537-1546
To systematically evaluate the clinical efficacy and safety of Ginkgo Leaf Tablets(GLT) in the treatment of acute cerebral infarction(ACI). Seven databases both at home and abroad were systematically retrieved from their establishment to March 2020. The data of the included studies were extracted after review and screening. The quality of the included studies was assessed with the Cochrane risk bias assessment tool, and then the included studies were put into Meta-analysis by RevMan 5.3 to evaluate the total cli-nical efficiency, neurological function score, blood lipids and incidence of adverse reactions in treatment of ACI by GLT. Finally, the GRADE system was adopted to evaluate the evidence quality of each outcome indicator and form recommendations. Ten studies involving 886 participants were included, all of which were of low quality. Meta-analysis results showed that,(1)in terms of the total clinical efficiency, GLT+Western medicine was superior to Western medicine alone(RR_(NDS)=1.20, 95%CI[1.06, 1.36], P=0.005; RR_(NIHSS)=1.35, 95%CI[1.09, 1.69], P=0.007), and there was no statistical difference between GLT+Xuesaitong Injection+Wes-tern medicine and Xuesaitong Injection+Western medicine(RR=1.16, 95%CI[1.00, 1.35], P=0.05).(2)In terms of improving neurological function score, GLT+Western medicine was superior to Western medicine alone(MD_(NIHSS[moderate(severe)])=-1.55, 95%CI[-2.22,-0.88], P<0.000 01; MD_(NIHSS(severe))=-7.51, 95%CI[-8.00,-7.02], P<0.000 01; MD_(NDS)=-1.36, 95%CI[-2.39,-0.33], P=0.01), and GLT+Danshen Injection+Western medicine was superior to Danshen Injection+Western medicine(MD_(NDS)=-3.09, 95%CI[-3.84,-2.34], P<0.000 01).(3)In terms of regulating blood lipids, GLT+Western medicine was superior to Wes-tern medicine alone(MD_(TC)=-1.40, 95%CI[-2.13,-0.66], P=0.000 2; MD_(TG)=-1.29, 95%CI[-1.86,-0.73], P<0.000 01; MD_(LDL-C)=-1.48, 95%CI[-2.91,-0.04], P=0.04; MD_(HDL-C)=0.07, 95%CI[0.02, 0.12], P=0.009).(4)In terms of incidence of adverse reactions, there was no statistical difference between GLT+Western medicine and Western medicine alone(RR=0.63, 95%CI[0.30, 1.32], P=0.22). The results of the evaluation showed that the evidence level of each outcome indicator was low, and the recommendation was at weak level. In conclusion, GLT+Western medicine could improve the total clinical efficiency, neurological function score, and blood lipid status, with a low incidence of adverse reactions. However, due to the small amount of included stu-dies, low study quality and low level of evidence, it is expected to carry out clinical studies with standardized design and large sample size in the future to further investigate the clinical efficacy and safety of GLT in the treatment of ACI.
Cerebral Infarction/drug therapy*
;
Ginkgo biloba
;
Humans
;
Plant Leaves
;
Tablets
;
Treatment Outcome
9.Expert consensus statement on Danshen Chuanxiongqin Injection in clinical practice.
Yang GAO ; Gui-Qian WANG ; Jian WANG ; Ming-Xue ZHANG ; Yan-Ming XIE ; Huan LIU ; Jun-Jie JIANG
China Journal of Chinese Materia Medica 2019;44(14):2937-2942
Danshen Chuanxiongqin Injection is a commonly used medicine in cerebral infarction and coronary heart disease,which is recommended by many disease guidelines/consensus for cardiovascular and cerebrovascular diseases. However,there are irrational drug using in clinic,which affects the efficacy and brings safety risks. Based on clinical research evidence and expert experience,recommendations/consensus suggestion are determined through the nominal group method. The expert consensus recommends the indications,intervention time for treatment,route of drug administration,usage and dosage,course of treatment and introduces the safety in clinical application,which could provide reference for clinical use of Danshen Chuanxiongqin Injection.
Cerebral Infarction
;
drug therapy
;
Consensus
;
Drugs, Chinese Herbal
;
therapeutic use
;
Humans
;
Injections
10.Systematic review and Meta-analysis on randomized controlled trials on effectiveness and safety of Kudiezi Injection in treatment of acute cerebral infarction.
Dan-Dan YU ; Yan-Ming XIE ; Yun-Ling ZHANG ; Xing LIAO ; Ying-Jie ZHI ; Hui ZHAO
China Journal of Chinese Materia Medica 2019;44(2):372-380
To systematically review the effectiveness and safety of Kudiezi Injection in treating patients with acute cerebral infarction( ACI). Four Chinese databases( CNKI,VIP,Wan Fang,Sino Med),three English databases( Cochrane Library,EMbase,Medline)and Clinical Trail.gov were systematically and comprehensively retrieved. The retrieval time was from the establishment of each database to November 2017. Randomized controlled trials( RCTs) for the treatment of acute cerebral infarction with Kudiezi Injection were screened out according to pre-established inclusion criteria and exclusion criteria. The quality of the included studies was assessed using the Cochrane Risk Assessment Tool,and the included studies were put into descriptive analysis or Meta-analysis using the Rev Man 5. 3 software. A total of 932 articles were retrieved,and finally 14 studies were included. Except for 2 multi-arm trials,the total sample size was 1 244 in the experimental group and 638 in the control group. The overall quality of the included studies was not high. The results of Meta-analysis showed that Kudiezi + conventional therapy for acute cerebral infarction was superior to conventional therapy in total effective rate( RR = 0. 86,95% CI[0. 77,0. 96],P = 0. 006); Kudiezi + conventional therapy for acute cerebral infarction was superior to conventional therapy in serum inflammatory factors( MDhs-CRP=-3. 77,95% CI[-4. 17,-3. 37],P < 0. 000 01; MDIL-18=-16. 18,95% CI[-19. 26,-13. 11],P<0. 000 01); Kudiezi + conventional therapy was superior to conventional therapy in Barthel index( MD = 12. 52,95%CI[8. 93,16. 10],P<0. 000 01). Adverse reactions included in the study reports showed mild adverse reactions. Based on the results of this study,Kudiezi Injection combined with conventional therapy or other Western medicine had a certain curative effect on acute cerebral infarction,with no serious adverse reactions. However,due to the low quality of the included research methodology,the conclusions of this study were not recommended. In addition,in order to produce high-quality evidence for the clinical application of Kudiezi Injections,more randomized controlled trials with a large sample size,scientific design and strict implementation were required to study the effectiveness and safety of Kudiezi Injection in the treatment of cerebral infarction.
Cerebral Infarction
;
drug therapy
;
Drugs, Chinese Herbal
;
therapeutic use
;
Humans
;
Injections
;
Randomized Controlled Trials as Topic